ADA2 and influenza: Vital to the treatment of influenza is the use of antiviralssuchas Oseltamivir (Tamiflu) and Zanamivir (Relenza); however, antiviralresistance is becoming an increasing problem for these therapeutics.The RNA-dependent RNA polymerase acidic N-terminal (PAN) endonuclease, a critical component of influenza viral replicationmachinery, is an antiviral target that was recently validated withthe approval of Baloxavir Marboxil (BXM).